Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis

Defrawy, A.O. El; Gheita, Tamer A.; Raslan, Hala M.; Ansary, Mervat M. El; Awar, A.H. El

doi:10.1007/s00393-015-1647-5

Cited by 28 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COMP protein was readily detectable in plasma and circulating COMP levels were significantly elevated in overweight/obese individuals compared to normal-weight controls. Furthermore, the observation that circulating COMP protein levels were positively correlated with BMI and total fat mass percentage in men and women is consistent with other reports that plasma COMP levels correlate positively with BMI [36] and decline upon weight loss [37] . Together these observations prompted the suggestion that COMP may represent a novel adipokine akin to THBS1 [10] .…”

Section: Discussionsupporting

confidence: 91%

Cartilage oligomeric matrix protein is differentially expressed in human subcutaneous adipose tissue and regulates adipogenesis

Denton

Pinnick

Karpe

2018

Molecular Metabolism

View full text Add to dashboard Cite

ObjectiveThe composition of the extracellular matrix (ECM) impacts adipocyte function and might determine adipose tissue (AT) function and distribution. Cartilage oligomeric matrix protein (COMP), a matricellular protein usually studied in bone and cartilage, is highly differentially expressed between subcutaneous abdominal and gluteal AT. This study aimed to explore COMP's role in human subcutaneous abdominal and gluteal AT and preadipocyte biology.MethodsCOMP mRNA levels were measured in whole AT and immortalised preadipocytes via quantitative (q)-PCR. Tissue and cellular COMP protein were measured via Western blot and immunohistochemistry; plasma COMP was measured by ELISA. The effect of COMP on adipogenesis in immortalised preadipocytes was evaluated by qPCR of adipogenic markers and cellular triacylglycerol (TAG) accumulation.ResultsqPCR analysis of paired subcutaneous abdominal and gluteal AT biopsies (n = 190) across a range of BMI (20.7–45.5 kg/m2) indicated ∼3-fold higher COMP expression in gluteal AT (P = 1.7 × 10−31); protein levels mirrored this. Immunohistochemistry indicated COMP was abundant in gluteal AT ECM and co-localised with collagen-1. AT COMP mRNA levels and circulating COMP protein levels were positively associated with BMI/adiposity but unrelated to AT distribution. COMP expression changed dynamically during adipogenesis (time × depot, P = 0.01). Supplementation of adipogenic medium with exogenous COMP protein (500 ng/ml) increased PPARG2 expression ∼1.5-fold (P = 0.0003) and TAG accumulation ∼1.25-fold in abdominal and gluteal preadipocytes (P = 0.02).ConclusionsWe confirmed that COMP is an ECM protein which is differentially expressed between subcutaneous abdominal and gluteal AT. Despite its depot-specific expression pattern, however, AT COMP mRNA levels and plasma COMP concentration correlated positively with overall obesity but not body fat distribution. Exogenous COMP enhanced adipogenesis. These data identify COMP as a novel regulator of AT and highlight the importance of the ECM to AT biology.

show abstract

Section: Discussionsupporting

confidence: 91%

Cartilage oligomeric matrix protein is differentially expressed in human subcutaneous adipose tissue and regulates adipogenesis

Denton

Pinnick

Karpe

2018

Molecular Metabolism

View full text Add to dashboard Cite

show abstract

“…A former study showed, comparable to our results, that serum COMP was higher in established RA (23.9 micg/mL) than in early-stage RA 15.1 micg/mL). This study also evaluated synovial COMP level which showed similar results to serum COMP level ( 16 ). Our study revealed that there is a good positive correlation between this biomarker and joint destruction in late RA.…”

Section: Discussionmentioning

confidence: 73%

“…In addition, some studies have indicated that COMP, in fact, decreases in advanced stages of RA ( 12 ). A former report noted that mean serum COMP was significantly higher in established RA (23.9 micg/mL) than in early stage RA (15.1 micg/mL) ( 16 ). Here, we decided to compare serum COMP level between RA patients and OA as well as healthy controls.…”

Section: Introductionmentioning

confidence: 99%

Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity

et al. 2017

View full text Add to dashboard Cite

BackgroundSerum cartilage oligomeric matrix protein (COMP) is a non-collagen glycoprotein produced by the cartilage, synovium, tendon, and meniscus. Recent studies showed that COMP is a reliable factor for monitoring cartilage damage.ObjectiveTo determine the relationship between serum COMP concentration and the severity of rheumatoid arthritis (RA).MethodsThis cross-sectional study lasted from 2013 to 2015 at the Rheumatology Clinic of Ghaem Hospital, Mashhad, Iran. The study population consisted of eligible patients who presented to our clinic during the study period. Four groups (150 subjects) were included as early RA (50 patients), late RA (50 patients), grades II and III OA (osteoarthritis) (25 cases, 17 grade II and 8 grade III joint destruction), and healthy controls (25 individuals). These were included consecutively. Serum COMP level was assessed by sandwich ELISA technique. In addition, ESR, hs-CRP, serum RF, and anti-CCP were assayed. X-rays of the knees (in OA) and hands (in RA) were examined for the degree of joint damage/erosion using the Short Erosion Scale (SES) in RA and Kellgren-Lawrence grading in OA. Analysis of variance (ANOVA) to compare mean COMP level among the groups and ROC (Receiver Operating Characteristic) analysis to determine the diagnostic accuracy of COMP in diagnosis of late RA were used by SPSS software (ver. 20.0).ResultsMean (±SD) serum COMP levels were 18 (±10.6) U/L in early RA, 19.3 (±9.6) U/L in late RA, 10.9 (±4.5) U/L in OA, and 4.2 (±3.8) in controls; p<0.001. Serum COMP level was higher in RA and OA groups when compared to control group. Mean (±SD) SES score was 13.5 (±7.5) in early RA and 16.4 (±9.7) in late RA (p=0.093). There was a significant positive correlation between COMP level and disease severity in early RA (r=0.677, p<0.001) as well as in late RA (r=0.753, p<0.001). Serum COMP level at a concentration of 15.25 U/L had a sensitivity of 68% and specificity of 70% to discriminate late RA from early RA (area under curve= 69% (95% CI: 58% to 79%; p=0.001).ConclusionCOMP had positive significant correlation with early and late RA severity. This serum biomarker can be a useful and easy tool for monitoring of RA patients either at early or late stages of the disease.

show abstract

“…High serum levels are associated with lower risk of myocardial infarction [ 68 ]. COMP was suggested as biomarker for disease progression of rheumatoid arthritis, osteoarthritis [ 69 , 70 ] and liver fibrosis [ 71 ], and early cartilage lesions in the knee [ 72 ]. Increased serum concentrations were found in patients with rapid hip joint destruction [ 73 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice

et al. 2018

View full text Add to dashboard Cite

ObjectivesSpinal muscular atrophy (SMA) is a devastating motor neuron disorder caused by homozygous loss of the survival motor neuron 1 (SMN1) gene and insufficient functional SMN protein produced by the SMN2 copy gene. Additional genetic protective modifiers such as Plastin 3 (PLS3) can counteract SMA pathology despite insufficient SMN protein. Recently, Spinraza, an SMN antisense oligonucleotide (ASO) that restores full-length SMN2 transcripts, has been FDA- and EMA-approved for SMA therapy. Hence, the availability of biomarkers allowing a reliable monitoring of disease and therapy progression would be of great importance. Our objectives were (i) to analyse the feasibility of SMN and of six SMA biomarkers identified by the BforSMA study in the Taiwanese SMA mouse model, (ii) to analyse the effect of PLS3 overexpression on these biomarkers, and (iii) to assess the impact of low-dose SMN-ASO therapy on the level of SMN and the six biomarkers.MethodsAt P10 and P21, the level of SMN and six putative biomarkers were compared among SMA, heterozygous and wild type mice, with or without PLS3 overexpression, and with or without presymptomatic low-dose SMN-ASO subcutaneous injection. SMN levels were measured in whole blood by ECL immunoassay and of six SMA putative biomarkers, namely Cartilage Oligomeric Matrix Protein (COMP), Dipeptidyl Peptidase 4 (DPP4), Tetranectin (C-type Lectin Family 3 Member B, CLEC3B), Osteopontin (Secreted Phosphoprotein 1, SPP1), Vitronectin (VTN) and Fetuin A (Alpha 2-HS Glycoprotein, AHSG) in plasma.ResultsSMN levels were significantly discernible between SMA, heterozygous and wild type mice. However, no significant differences were measured upon low-dose SMN-ASO treatment compared to untreated animals. Of the six biomarkers, only COMP and DPP4 showed high and SPP1 moderate correlation with the SMA phenotype. PLS3 overexpression neither influenced the SMN level nor the six biomarkers, supporting the hypothesis that PLS3 acts as an independent protective modifier.

show abstract

Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis

Abstract: COMP is a promising biomarker for disease activity in RA, making it a potential therapeutic target. The obvious correlation with the BMI throws light on the importance of weight control not only in osteoarthritis (OA), but also in RA.

Cited by 28 publications

References 43 publications

Cartilage oligomeric matrix protein is differentially expressed in human subcutaneous adipose tissue and regulates adipogenesis

Cartilage oligomeric matrix protein is differentially expressed in human subcutaneous adipose tissue and regulates adipogenesis

Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity

Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice

Contact Info

Product

Resources

About